Related Experiment Videos
Lichen planus induced by interferon-alpha-2a therapy for chronic active hepatitis C
T Barreca1, G Corsini, R Franceschini
1Department of Internal Medicine, University of Genova, Italy.
European Journal of Gastroenterology & Hepatology
|April 1, 1995
Summary
Hepatitis C virus (HCV)-positive patients on interferon therapy may develop lichen planus. This case report highlights the potential adverse skin reaction during treatment for chronic active hepatitis.
Area of Science:
- Hepatology
- Dermatology
- Viral Hepatitis
Background:
- Chronic active hepatitis C virus (HCV) infection is a significant global health concern.
- Interferon therapy has been a cornerstone treatment for chronic hepatitis C.
- Understanding treatment-related adverse events is crucial for patient management.
Observation:
- A 64-year-old woman with HCV-positive chronic active hepatitis was treated with interferon-alpha-2a.
- Four months into treatment, she developed characteristic cutaneous lesions consistent with lichen planus.
- Skin biopsy confirmed the diagnosis of lichen planus.
Findings:
- Interferon therapy in an HCV-positive patient precipitated the development of lichen planus.
- Discontinuation of interferon led to improvement of skin lesions, though not complete resolution.
- This suggests a potential causal link between interferon and lichen planus in this context.
Implications:
- Clinicians should be vigilant for lichen planus development in HCV patients undergoing interferon treatment.
- This case underscores the importance of considering drug-induced dermatological conditions.
- Further research may elucidate the mechanisms underlying this interferon-induced adverse reaction.